Table 2.

Resistant cohort: baseline features

	Dasatinib	Nilotinib	Overall
	(N = 62)	(N = 75)	(N = 137)
Gender—no. (%)
Female	21 (33.87%)	29 (38.67%)	50 (36.50%)
Male	41 (66.13%)	46 (61.33%)	87 (63.50%)
Age
Median—y	57	51	52
Range—y	24‐82	21‐83	21‐83
<65 y	46 (74.19%)	66 (88.00%)	112 (81.75%)
≥65 y	16 (25.81%)	9 (12.00%)	25 (18.25%)
Sokal score
Low‐risk	12 (19.35%)	23 (30.67%)	35 (25.55%)
Intermediate	23 (37.10%)	23 (30.67%)	46 (33.58%)
High‐risk	27 (43.55%)	29 (38.67%)	56 (40.88%)
Mean (Median) days at switch	386 (286.5)	335 (293)	358 (293)
Switch within 365 d from treatment start	34 (54.8%)	47 (62.7%)	81 (59.1%)